The authors aimed to compare dacomitinib with erlotinib in a phase 3 study. Irreversible EGFR inhibition with dacomitinib was not superior to erlotinib in an unselected patient population with advanced non–small–cell lung cancer or in patients with KRAS wild–type tumours. Further study of irreversible EGFR inhibitors should be restricted to patients with activating EGFR mutations.

READ FULL ARTICLE Curated publisher From Mdlinx